Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine hydrochloride injection); FDA Will Be Unable To Approve Any Drug Applications Referencing BENDEKA Until ODE Expires In 2022